Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 160, Issue 5 I, 1999, Pages 1500-1506

  Schermuly, Ralph Theo ^b   Ghofrani, Hossein Ardeschir ^b   Enke, Beate ^b   Weissmann, Norbert ^b   Grimminger, Friedrich ^b   Seeger, Werner ^b   Schudt, Christian ^b   Walmrath, Dieter ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; EPOSTENOL; MOTAPIZONE; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; ROLIPRAM; TOLAFENTRINE; UNCLASSIFIED DRUG; ZAPRINAST; ZARDAVERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HEART OUTPUT; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RABBIT; VASODILATATION;

EID: 0032717676     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.160.5.9901102     Document Type: Article

References (40)

1. D'Alonzo, G. E., R. J. Barst, S. M. Ayres, E. H. Bergofsky, B. H. Brundage, K. M. Detre, A. P. Fishman, R. M. Goldring, B. M. Groves, J. T. Kernis, et al. 1991. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115(5):343-349.
2. Lee, P., P. Langevitz, C. A. Alderdice, M. Aubrey, P. A. Baer, M. Baron, D. Buskila, J. P. Dutz, I. Khostanteen, S. Piper, et al. 1992. Mortality in systemic sclerosis (scleroderma). Q. J. Med. 82(298):139-148.
3. Olschewski, H., and W. Seeger. 1994. Pathophysiology of pulmonary hypertension. Z. Kardiol. 83(Suppl. 6):181-191.
4. Christman, B. W., C. D. McPherson, J. H. Newman, G. A. King, G. R. Bernard, B. M. Groves, and J. E. Loyd. 1992. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 327(2):70-75.
5. Giaid, A., and D. Saleh. 1995. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333(4):214-221.
6. Wagner, R. S., C. J. Smith, A. M. Taylor, and R. A. Rhoades. 1997. Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries. J. Pharmacol. Exp. Ther. 282(3):1650-1657.
7. Rich, S., E. Kaufmann, and P. S. Levy. 1992. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med. 327(2):117-119.
8. Rubin, L. J., J. Mendoza, M. Hood, M. McGoon, R. Barst, W. B. Williams, J. H. Diehl, J. Crow, and W. Long. 1990. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): Results of a randomized trial. Ann. Intern. Med 112(7): 485-491.
9. Barst, R. J., L. J. Rubin, W. A. Long, M. D. McGoon, S. Rich, D. B. Badesch, B. M. Groves, V. F. Tapson, R. C. Bourge, B. H. Brundage, S. K. Koerner, D. Langleben, C. A. Keller, B. F. Uretsky, L. M. Clayton, M. M. Jobsis, S. D. Blackburn, Jr., D. Shortino, and J. W. Crow. 1996. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 334(5):296-302.
10. McLaughlin, V. V., D. E. Genthner, M. M. Panella, and S. Rich. 1998. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N. Engl. J. Med. 338(5):273-277.
11. Troncy, E., J. P. Collet, S. Shapiro, J. G. Guimond, L. Blair, T. Ducruet, M. Francoeur, M. Charbonneau, and G. Blaise. 1998. Inhaled nitric oxide in acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 157:1483-1488.
12. Bigatello, L. M., W. E. Hurford, and D. Hess. 1997. Use of inhaled nitric oxide for ARDS. Respir. Care Clin. N. Am. 3(3):437-458.
13. Walmrath, D., T. Schneider, J. Pilch, H. Grimminger, and W. Seeger. 1993. Aerosolized prostacyclin reduces pulmonary artery pressure and improves gas exchange in the adult respiratory distress syndrome (ARDS). Lancet 342:961-962.
14. Walmrath, D., T. Schneider, R. Schermuly, H. Olschewski, F. Grimminger, and W. Seeger. 1996. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 153:991-996.
15. Zwissler, B., G. Kemming, O. Habler, M. Kleen, M. Merkel, M. Haller, J. Briegel, M. Welte, and K. Peter. 1996. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 154:1671-1677.
16. Walmrath, D., T. Schneider, J. Pilch, R. Schermuly, F. Grimminger, and W. Seeger. 1995. Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis. Am. J. Respir. Crit. Care Med. 151:724-730.
17. Olschewski, H., H. A. Ghofrani, D. Walmrath, B. Temmesfeld-Wollbruck, K. Grimminger, and W. Seeger. 1998. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Med. 24(6):631-634.
18. Olschewski, H., D. Walmrath, R. Schermuly, F. Grimminger, and W. Seeger. 1996. Aerosolized prostacyclin and iloprost in primary pulmonary hypertension. Ann. Intern. Med. 124:820-824.
19. Olschewski, H., H. A. Ghofrani, D. Walmrath, R. Schermuly, R. Schulz, F. Grimminger, and W. Seeger. 1998. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis (abstract). Am. J. Respir. Crit. Care Med. 157(3):A595.
20. Manganiello, V. C., T. Murata, M. Taira, P. Belfrage, and H. Degerman. 1995. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch. Biochem. Biophys. 322(1):1-13.
21. Beavo, J. A. 1995. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75(4):725-748.
22. Conti, M., G. Nemoz, C. Sette, and E. Vicini. 1995. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr. Rev. 16(3):370-389.
23. Torphy, T. J. 1998. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 157(2):351-370.
24. Rabe, K. F., H. Tenor, G. Dent, C. Schudt, M. Nakashima, and H. Magnussen. 1994. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am. J. Physiol. 266:L536-L543.
25. Lindeborg, D. M., B. P. Kavanagh, K. Van Meurs, and R. G. Pearl. 1995. Inhaled nitric oxide does not alter the longitudinal distribution of pulmonary vascular resistance. J. Appl. Physiol. 78(1):341-348.
26. Rimar, S., and C. N. Gillis. 1995. Site of pulmonary vasodilation by inhaled nitric oxide in the perfused lung. J. Appl. Physiol. 78(5): 1745-1749.
27. Walmrath, D., R. Schermuly, J. Pilch, F. Grimminger, and W. Seeger, 1997. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur. Respir. J. 10(5):1084-1092.
28. Ichinose, F., C. Adrie, W. E. Hurford, and W. M. Zapol. 1995. Prolonged pulmonary vasodilator action of inhaled nitric oxide by zaprinast in awake lambs. J. Appl. Physiol. 78(4):1288-1295.
29. Ichinose, F., C. Adrie, W. E. Hurford, H. K. Bloch, and W. M. Zapol. 1998. Selective pulmonary vasodilation induced by acrosolized zaprinast. Anesthesiology 88(2):410-416.
30. Kleen, M., O. Habler, C. Hofstetter, R. Pusch, M. Mueller, M. Welte, and B. Zwissler. 1998. Efficacy of inhaled prostanoids in experimental pulmonary hypertension. Crit. Care Med. 26(6):1103-1109.
31. Pan, X., E. Arautz, J. J. Krzanowski, D. F. Fitzpatrick, and J. B. Polson. 1994. Synergistic interaction between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE 3 and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem. Pharmacol. 48(4):827-835.
32. Braner, D. A., J. R. Fineman, R. Chang, and S. J. Soifer. 1993. M&B 22948, a cGMP phosphodiesterase inhibitor, is a vasodilator in lambs. Am. J. Physiol. 264(1, Pt. 2):H252-H258.
33. Thusu, K. G., F. C. Morin, J. A. Russell, and R. H. Steinhorn. 1995. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. Am. J. Respir. Crit. Care Med. 152(5, Pt. 1):1605-1610.
34. Ziegler, J. W., D. D. Ivy, J. J. Fox, J. P. Kinsella, W. R. Clarke, and S. H. Abman. 1995. Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilation in the ovine fetus. Am. J. Physiol. 269 (2, Pt. 2):H473-H479.
35. Ziegler, J. W., D. D. Ivy, J. J. Fox, J. P. Kinsella, W. R. Clarke, and S. H. Abman. 1998. Dipyridamole potentiates pulmonary vasodilation induced by acetylcholine and nitric oxide in the ovine fetus. Am. J. Respir. Crit. Care Med. 157(4, Pt. 1):1104-1110.
36. Clarke, W. R., S. Uczono, A. Chambers, and P. Doepfner. 1994. The type 3 phosphodiesterase inhibitor mitrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. Pulm. Pharmacol. 7(2):81-89.
37. Ivy, D. D., J. P. Kinsella, J. W. Ziegler, and S. H. Abman. 1998. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. J. Thorac. Cardiovasc. Surg. 115(4):875-882.
38. Eckly, A. E., and C. Lugnier. 1994. Role of phosphodiesterase 3 and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway. Br. J. Pharmacol. 113(2):445-450.
39. McMahon, E. G., M. A. Palomo, P. Meht, and G. M. Olins. 1989. Depressor and natriuretic effects of M&B 22,948, a guanosine cyclic 3′,5′-monophosphate-selective phosphodiesterase inhibitor. J. Pharmarol. Exp. Ther. 251(3):1000-1005.
40. Thorphy, T. J., and B. J. Undem. 1991. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 46:512-523.